Actively Recruiting
A Study of Maribavir in Adults and Children With Post-transplant Cytomegalovirus (CMV) Infection in Argentina
Led by Takeda · Updated on 2025-07-09
10
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main aim of this study is to learn about the safety of Maribavir in adults and children with post-transplant CMV infection in routine clinical practice in Argentina. The other aim is to study the effectiveness of the treatment with Maribavir in routine clinical practice in Argentina. Participants will be treated by their doctors according to normal medical practice. Study data will be collected either from information already available in the medical records or during study conduct.
CONDITIONS
Official Title
A Study of Maribavir in Adults and Children With Post-transplant Cytomegalovirus (CMV) Infection in Argentina
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years or older and children 12 years or older weighing at least 35 kg
- Post-transplant CMV infection or disease refractory to treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet
- Have received at least one dose of Maribavir according to approved indications
- Signed informed consent or assent as required by national regulatory authorities (ANMAT)
You will not qualify if you...
- There are no specific exclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IC Projects
City of Buenos Aires, Argentina, C11119ACN
Actively Recruiting
Research Team
T
Takeda Contact
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here